Endomed - Company finances
|
EUR
|
2022
From: 2022-09-19
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|
|
Financial data
|
||||
| Sales revenue | 0 | 16,376 | 41,496 | 43,220 |
| Profit before tax | -170 | 5,123 | 29,493 | 32,655 |
| Net profit | -170 | 4,875 | 28,018 | 30,696 |
| Equity | -170 | 4,706 | 32,724 | 46,420 |
| Liabilities | 539 | 15,167 | 5,476 | 2,126 |
| Non-current assets | 189 | 7,006 | 7,504 | 6,600 |
| Current assets | 180 | 12,867 | 30,696 | 41,946 |
| Total assets | 369 | 19,873 | 38,200 | 48,546 |
|
Taxes paid
|
||||
| STI taxes | - | 118 | 248 | 1,475 |
|
Financial indicators
|
||||
| Revenue change y/y | - | - | +153.4% | +4.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -46.1% | 24.5% | 73.3% | 63.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 103.6% | 85.6% | 66.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | 29.8% | 67.5% | 71.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | 31.3% | 71.1% | 75.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 3.2 | 0.2 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Endomed - Social security debts
The company had no debts to Sodra
Endomed - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Endomed, MB (code 306148126) is a Small partnership engaged in medical specialists activities. In the latest financial year 2025, the company generated revenue of €43.2K and net profit of €30.7K, corresponding to a profit margin of 71.0%. Revenue increased by 4.2% year on year, while over the last two years it rose by 163.9%, showing a strong expansion from the 2023 level of €16.4K. Net profit also improved from €4.9K in 2023 to €28.0K in 2024 and €30.7K in 2025, indicating sustained profitability growth. The balance sheet strengthened further in 2025: total assets reached €48.5K, equity increased to €46.4K, and liabilities declined to €2.1K. The equity ratio was 95.6% and debt-to-equity stood at 0.05, reflecting very low leverage. Return on equity was 66.1% and return on assets 63.2%, while asset turnover was 0.89x. The company held €6.6K in long-term assets and €41.9K in short-term assets at year-end 2025.